A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led ...

The drug works by targeting beta amyloid -- a protein that builds up in the brains of people with Alzheimer's disease and is thought to be the triggering event leading to neuronal dysfunction and cell ...

This mechanism, which involves extracellular accumulation of a 56 kDa soluble amyloid-β (Aβ ... Their results suggest that other soluble protein assemblies could also have a role in inducing ...

脑淀粉样血管病（cerebral amyloid angiopathy，CAA）是一种常见的脑小血管病 ，其特征性病变是β-淀粉样蛋白（amyloid β-protein，Aβ）在大脑皮质及覆盖其上的软脑膜的中小动脉、微细动脉和毛细血管管壁渐进性沉积 ...

One of the major components of these protein buildups was thought to be a protein called amyloid beta, or Aβ42, which clump together into what is known as amyloid plaques. However, a new study ...

but there is a big gulf in understanding whether the generation of protein aggregates causes the disease per se.” In the brains of patients with Alzheimer’s disease, a peptide called amyloid-beta ...

How exactly do amyloid plaques affect surrounding brain tissue ... “This is an important contribution that directly links the age of aggregated protein with overall disease pathology—reinforcing that ...

Amyloid fibrils appear in many neurodegenerative ... When the group mutated any of these three amino acids in purified protein experiments, the mutant synucleins packed together much faster ...

Preclinical studies have shown AT-02 is able to bind to multiple amyloid types and can induce macrophage mediated amyloid phagocytosis and removal. The Food and Drug Administration has granted Orphan ...

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood ...